Warning letter · FDA Warning Letters

NeuroHydrate LLC: FDA Warning Letter 613092 (Apr 27, 2021)

Agency action: Apr 27, 2021Record ID: fda_warning_-55a4eb061665d53d
View official source ↗

What happened

Original notice title

NeuroHydrate LLC MARCS-CMS 613092, April 27, 2021

From the archived source record

The matters cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. Failure to promptly correct these matters may result in legal action without further notice, including, without limitation, seizure and injunction. Within 15 working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
FDA closeout listed
Source checked
Jul 16, 2026
Record revision
03078d0e8a07

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
HM-FORMULA; …our Migraine Prevention Therapy Program (MPT)…; NeuroHydrate created HM-Formula (HMF), a new migraine supplement…
Company
NeuroHydrate LLC
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.